Ironwood Pharmaceuticals, Inc. (IRWD)
4.125
-0.16
(-3.85%)
USD |
NASDAQ |
Aug 24, 16:00
4.14
+0.02
(+0.36%)
After-Hours: 20:00
Ironwood Pharmaceuticals Gross Profit Margin (Quarterly) : 99.60% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 99.60% |
| March 31, 2026 | 99.58% |
| December 31, 2025 | 99.04% |
| September 30, 2025 | 99.61% |
| June 30, 2025 | 99.45% |
| March 31, 2025 | 98.84% |
| December 31, 2024 | 99.46% |
| September 30, 2024 | 99.45% |
| June 30, 2024 | 99.46% |
| March 31, 2024 | 99.31% |
| December 31, 2023 | 99.56% |
| September 30, 2023 | 99.55% |
| June 30, 2023 | 99.75% |
| March 31, 2023 | 99.73% |
| December 31, 2022 | 99.68% |
| September 30, 2022 | 99.67% |
| June 30, 2022 | 99.63% |
| March 31, 2022 | 99.64% |
| December 31, 2021 | 99.69% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 98.87% |
| September 30, 2020 | 98.24% |
| June 30, 2020 | 99.28% |
| Date | Value |
|---|---|
| March 31, 2020 | 96.35% |
| December 31, 2019 | 90.59% |
| September 30, 2019 | 97.19% |
| June 30, 2019 | 88.93% |
| March 31, 2019 | 97.48% |
| December 31, 2018 | 83.05% |
| September 30, 2018 | 89.72% |
| June 30, 2018 | 90.70% |
| March 31, 2018 | 91.20% |
| December 31, 2017 | 86.62% |
| September 30, 2017 | 90.81% |
| June 30, 2017 | 93.97% |
| March 31, 2017 | 92.60% |
| December 31, 2016 | 98.48% |
| September 30, 2016 | 91.81% |
| June 30, 2016 | 93.46% |
| March 31, 2016 | 95.71% |
| December 31, 2015 | 94.75% |
| September 30, 2015 | 92.95% |
| June 30, 2015 | 70.62% |
| March 31, 2015 | 89.97% |
| December 31, 2014 | 65.48% |
| September 30, 2014 | 81.27% |
| June 30, 2014 | -53.77% |
| March 31, 2014 | 76.12% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| AbbVie, Inc. | 74.71% |
| Rigel Pharmaceuticals, Inc. | 89.17% |
| Marker Therapeutics, Inc. | -- |
| Verastem, Inc. | 89.92% |
| Theriva Biologics, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | 34.99% |
| Return on Invested Capital | 41.21% |
| Profit Margin (Quarterly) | 45.37% |
| Operating Margin (Quarterly) | 70.16% |
| Return on Net Operating Assets | 119.0% |